HCMHUTCHMED (China) Limited
Price
-18%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 9% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for HCM today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally. Our operational achievements and capabilities to date include:
In the company’s own words · 20-F filed Mar 5, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
HUTCHMED (China) Limited (HCM) reported revenue of $271M in H2 2025 (quarter ended Dec 31, 2025), down 11% from the same quarter a year earlier. That came with a gross margin of 38% and net income of $2.0M (0.7% of revenue). For the full year FY2025, revenue was $549M (−13% year on year) and net income $457M.
Drug Manufacturers, Specialty & Generic
Ranks #38 of 41 by RyuScore